claim
While the authors focused their study outlines on 5-HT2AR agonist 'classic' psychedelics like psilocybin, LSD, and DMT, these study frameworks could be applied to other novel therapies such as ketamine, MDMA, and ibogaine.

Authors

Sources

Referenced by nodes (4)